Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents aged 10 through 25 years of age inclusive at the time of enrollment.~Exclusion Criteria:~* History of any meningococcal vaccine administration;~* Current or previous, confirmed or suspected disease caused by N. meningitidis;~* Pregnant or nursing (breastfeeding) mothers;~* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study;~* Any serious, chronic, or progressive disease;~* Known or suspected impairment/alteration of the immune system;~* Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;~* History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- ABCWY+OMV (Type: EXPERIMENTAL): Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart.
- ABCWY+qOMV (Type: EXPERIMENTAL): Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart.
- rMenB+OMV (Type: ACTIVE_COMPARATOR): Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart.
- MenACWY (Type: ACTIVE_COMPARATOR): Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).